Ukraine: Still Open for Clinical Trials
The recent geopolitical developments in Ukraine have seriously influenced the conditions and the environment for clinical trials in Ukraine and in Russia.
The recent geopolitical developments in Ukraine have seriously influenced the conditions and the environment for clinical trials in Ukraine and in Russia.
In a webinar today, Natalia Fetkovska, Senior Partner at SanaClis, a CRO providing clinical trial services for Central and Eastern Europe (CEE), highlighted the problems.
Ukraine’s proportion of CEE clinical trials has grown over the past two years and now lags only behind Poland and Russia. But on May 12, the Ukraine Minister of Health instructed that no new studies would be approved for Crimea or Sevastopol (a city on the Crimean peninsula, with separate municipal powers from Crimea) and that recruitment of new patients into current studies should also cease.
Fetkovska suggested however that while some sponsors have suspended recruitment in Eastern Ukraine, they should still consider Ukraine for their trials. She noted that the investigator and patient population was more than willing to participate in clinical trials because they are feeling the economic impact of sanctions.
To minimize risks for conducting trials in the Ukraine, Fetkovska recommended:
• Avoid Crimea for new studies.
• Avoid sites in the critical cities of Eastern Ukraine, such as Luhansk, and Donetsk.
• Check logistic partners to make sure they are not sanctioned.
• Check site payments to make sure the banks are not sanctioned.
• Check the IT reliability of local partners, cloud-based solutions could or could not be positive based on regulatory concerns.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Sanofi Advances Mid- to Late-Stage Respiratory Pipeline, Targeting Unmet Need in Asthma, COPD
April 21st 2025New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab advance into chronic rhinosinusitis, chronic obstructive pulmonary disease, and bronchiectasis.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
April 18th 2025Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks achieved non-inferior visual acuity outcomes compared to Eylea in patients with macular edema following retinal vein occlusion.
